



RECEIVED

FEB 06 2004

TECH CENTER 1600/2900 PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: J. Timothy GREENAMYRE, et al.

Serial No.: 09/148,973

Group No.: 1627

Filed: September 4, 1998

Examiner:

For: METHODS OF ADMINISTERING AN AMPA RECEPTOR ANTAGONIST  
TO TREAT DYSKINESIAS ASSOCIATED WITH DOPAMINE AGONIST  
THERAPY

Attorney Docket No.: U 946765-7

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants respectfully call the Examiner's attention to the references cited on  
attached PTO Form 1449. Copies of the references are also attached.

The references show that tardive dyskinesia (TD) is one in a broad category of  
movement disorders thought to involve pathology of basal ganglia and that, as of the filing

**CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10\***  
(When using Express Mail, the Express Mail label number is **mandatory**;  
Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

## MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P. O.  
Box 1450, Alexandria, VA 22313-1450.

## 37 C.F.R. 1.8(a)

- ☒ with sufficient postage as first class mail.


## 37 C.F.R. 1.10\*

- ☐ as "Express Mail Post Office to Addressee"  
Mailing Label No. \_\_\_\_\_ (mandatory)

## TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Date: January 28, 2004

  
\_\_\_\_\_  
CLIFFORD J. MASS  
(type or print name of person certifying)


**\*WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. 1.10(b).  
"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

January 28, 2004

date of the present application, it was poorly understood how basal ganglia control movements. Indeed, the references show that it was thought that the manifestation of abnormal movement disorders, such as TD, at a minimum involved several neurotransmitter systems and that vulnerability to such disorders might be multifaceted. The references also show that TD is characterized by its etiology.

The attached references, when viewed in connection with the other references cited by the Examiner, would teach away from an expectation that a treatment for other neurological disorders, could be successfully used to treat tardive dyskinesia. Thus, for example, U.S. Patent 5,712,282 teaches that a medicine used in the treatment of Parkinson's disease can aggravate the symptoms of tardive dyskinesia ('282 patent at column 2, lines 12-31).

Respectfully submitted,



Clifford J. Mass  
Ladas & Parry  
26 West 61<sup>st</sup> Street  
New York, N.Y. 10023  
Reg. No.: 30,086 (212) 708-1890